<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Maternal &amp; Fetal Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B3CFAB86-E47C-4A51-BF72-E26E833B6951"><gtr:id>B3CFAB86-E47C-4A51-BF72-E26E833B6951</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Gayther</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E6DA6B2D-711D-4FB2-852C-037C401D80C5"><gtr:id>E6DA6B2D-711D-4FB2-852C-037C401D80C5</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:surname>Ramus</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F7A75A2D-96FC-4A42-84D7-AF14B45C1984"><gtr:id>F7A75A2D-96FC-4A42-84D7-AF14B45C1984</gtr:id><gtr:firstName>Leigh</gtr:firstName><gtr:surname>Pearce</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8840EEA3-4086-4264-8D80-DB3FFF422E7D"><gtr:id>8840EEA3-4086-4264-8D80-DB3FFF422E7D</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Pharoah</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801875"><gtr:id>A6C5B08A-6CF2-4A96-8843-25E3BF462F69</gtr:id><gtr:title>Molecular Epidemiology And Clinical Outcome In Epithelial Ovarian Cancers</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801875</gtr:grantReference><gtr:abstractText>Ovarian cancer kills between 4 and 5,000 women a year in the UK. It is one of the more lethal cancers in that when a women is diagnosed with the disease, she usually has a low chance of surviving more than 5 years. This statistic has changed very little in 4 decades. One approach to reducing death caused by cancer is to detect the disease at its earliest stages of development, when it is most treatable. However, many of the symptoms of early stage ovarian cancer are vague and there is no national screening programme that targets the detection of these cancers. If we could identify the proportion of the population that is a greatest risk of getting the disease, one could use a targeted strategy to screen these women and find any early signs of cancer as it develops. A person?s genetic make-up can increase their chance of getting one of many common diseases including diabetes, heart disease and breast cancer. By screening several million letters of DNA code that show variation from person to person, it is possible to find those letters that appear to be more common in individuals with certain diseases. This is what we have been doing for ovarian cancer; comparing the DNA code of thousands of women with the disease to women without disease. We now plan to take this information and find the handful of letters that seem to suggest a woman is at greatest risk of getting ovarian cancer. We will also test whether there are factors in her lifestyle- for example whether or not she has had children, or used the oral contraceptive pill- that also changes her risk of getting ovarian cancer. Once we have done this, we will be able to test whether it is feasible to use the markers we find to screen for the highest risk women throughout the whole population. To do these studies requires a large international effort, because we have to screen several thousands of women with disease and volunteers that have taken part in these studies. We are using the combined power of 11 different studies from around the world in order to perform this research. It is hoped that the findings will not only have an impact in the UK, but in other countries where ovarian cancer is also a major health problem</gtr:abstractText><gtr:technicalSummary>Epithelial ovarian cancer is responsible for 4-5,000 deaths in the UK each year. The disease is assoicated with a particularly poor outcome after diagnosis compared to other common cancers and the survival rates have improved little in 40 years. Identifying genetic and/or environmental risk factors for ovarian cancer in the population, could lead to improvements in clinical outcome through strategies aimed at early detection and prevention of the disease. Similarly, by identifying profiles of genetic changes that take place during ovarian tumour development, it may be possible to predict which patients are likely to respond to different treament regimens and to establish targeted intervention strategies based on these predictions.
The known ovarian cancer susceptibility genes are thought to explain 40% of the excess familial risk of the disease. The residual familial risks are thought to be driven by variants at multiple loci, each conferring more moderate disease risks ? the so called ?common disease common variant? hypothesis. The last year has seen a plethora of studies published that have identified several new genetic susceptibility loci for common diseases including breast, prostate and colorectal cancers; and so it is likely that similar common genetic susceptibility variants exist for ovarian cancer.
As part of an international collaboration of 11 studies comprising more than 7,000 ovarian cancer cases and 7,000 controls, we have performed a genome wide association study (GWAS) to identify moderate/low penetrance ovarian cancer susceptibility allele and have found strong evidence that multiple genetic susceptibility loci exist (11 loci with a P-value less than 10-7). 
The goal of this research proposal is to use the combined power in sample numbers achieved by this collaboration to follow-up on the data emerging from this GWAS to address the following aims: (1) To identify the putative causal variants associated with ovarian cancer risk by fine mapping the genetic variation at candidate susceptibility loci. (2) To evaluate the interaction between genetic variation and known ovarian cancer reproductive/lifestyle factors. (3) To evaluate the interactions between germline genetic variation and somatic genetic features of ovarian tumours following DNA profiling of 2,000 invasive ovarian cancers. (4) To evaluate associations between germline genetic variation and somatic genetic variation in tumours with clinical characteristics of disease (e.g. tumour sub-type; patient outcome). Positive findings from this study will be validated in two large, well-established consortia: the international Ovarian Cancer Association Consortium (OCAC) and the European wide Collaborative Oncological Gene-environment Study (COGS).</gtr:technicalSummary><gtr:fund><gtr:end>2012-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>928036</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7E95D076-1569-45D0-A159-9D3B20FC1A54</gtr:id><gtr:title>Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c36e8bd6d51a0f7f8900b01c297c1c15"><gtr:id>c36e8bd6d51a0f7f8900b01c297c1c15</gtr:id><gtr:otherNames>Phelan CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>dvw8KJVpkk2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD082FA8-18C3-43E7-AFC0-0E17B4381C5E</gtr:id><gtr:title>A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.</gtr:title><gtr:parentPublicationTitle>BMC cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4a9a3f8c09bdee7e2525738a05bed1d"><gtr:id>e4a9a3f8c09bdee7e2525738a05bed1d</gtr:id><gtr:otherNames>Batra J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2407</gtr:issn><gtr:outcomeId>THMXEphbrEQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC04714C-02D9-403B-A40C-B2B8D2A8451E</gtr:id><gtr:title>Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cdf29049d99ebf212ba6d85da0fc603"><gtr:id>9cdf29049d99ebf212ba6d85da0fc603</gtr:id><gtr:otherNames>Beesley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>DUHKq3GttGn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4030828-DF93-4DCE-ABD9-DE5277F20225</gtr:id><gtr:title>A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d540bbeacbb18287a21a56205f8e619"><gtr:id>4d540bbeacbb18287a21a56205f8e619</gtr:id><gtr:otherNames>Antoniou AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>FmSJbX9k8gq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F848870B-BF7C-43E4-A551-BF1E237CF069</gtr:id><gtr:title>Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1863af4d95688c2d34fd7dc131d163b"><gtr:id>f1863af4d95688c2d34fd7dc131d163b</gtr:id><gtr:otherNames>Lurie G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>Qm78wt6C78V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE133F2A-0F28-4155-B426-1F334AAD7BA7</gtr:id><gtr:title>Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea186742aeee90cbaace915ded49ca04"><gtr:id>ea186742aeee90cbaace915ded49ca04</gtr:id><gtr:otherNames>Cox DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>jbzBZx5TiwG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A047AFF6-6B40-42AD-B475-CC66985FFF8A</gtr:id><gtr:title>Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c1f3f8b1cd8dfe465e4ab56d869fc1c"><gtr:id>7c1f3f8b1cd8dfe465e4ab56d869fc1c</gtr:id><gtr:otherNames>Balogun N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>k5vgATkb268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7525A828-9168-439A-8B98-1147FA30943E</gtr:id><gtr:title>Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b4d77562eb680afc12df20064e2eb0a"><gtr:id>7b4d77562eb680afc12df20064e2eb0a</gtr:id><gtr:otherNames>Cunningham JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>JU6BHmyW1AX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6AF74C9-7A9E-44EC-9D71-837C71E2C6DB</gtr:id><gtr:title>Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ff4016bbbbb9b7881d3b611690d5b15"><gtr:id>7ff4016bbbbb9b7881d3b611690d5b15</gtr:id><gtr:otherNames>Amankwah EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>FKZrehFMdre</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A3BC398-0922-442D-A634-6499CD7325CB</gtr:id><gtr:title>Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd5ca507be8fc837adc2e664f73846d2"><gtr:id>dd5ca507be8fc837adc2e664f73846d2</gtr:id><gtr:otherNames>Ramus SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>jjt8F5RYZ4Z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97415882-F206-4D40-934E-C5BE9EB7D8C8</gtr:id><gtr:title>Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort.</gtr:title><gtr:parentPublicationTitle>Fertility and sterility</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/234c2ae7dfa6b51a0cea69cd85a80bbf"><gtr:id>234c2ae7dfa6b51a0cea69cd85a80bbf</gtr:id><gtr:otherNames>Near AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0015-0282</gtr:issn><gtr:outcomeId>A5KVy2586eH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDC5CC38-E3EB-4659-8551-AACF85860AEE</gtr:id><gtr:title>Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16c979ea93aa93434dc1855083c8bab3"><gtr:id>16c979ea93aa93434dc1855083c8bab3</gtr:id><gtr:otherNames>Notaridou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>V8Rdqf4MTpb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D074B6F9-EEEB-4C06-873B-3C75A337955C</gtr:id><gtr:title>The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f6f6a351492e203e8f6a91422cbf702"><gtr:id>0f6f6a351492e203e8f6a91422cbf702</gtr:id><gtr:otherNames>Pharoah PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>dJonRmHUq2b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B156A42-681B-47EF-AC95-50BAB94C26F2</gtr:id><gtr:title>A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90fb521fb4609dc795b90be3158eb5e1"><gtr:id>90fb521fb4609dc795b90be3158eb5e1</gtr:id><gtr:otherNames>Song H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>MJ18wecV4nP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6DCFCDC-8044-45B8-8E37-575AF5ECF8DB</gtr:id><gtr:title>A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b02c1d20ed72a4067ce2c0bc31ef01f5"><gtr:id>b02c1d20ed72a4067ce2c0bc31ef01f5</gtr:id><gtr:otherNames>Goode EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>ptRvpipFqR3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CF1B724-A282-45D7-8437-836584304735</gtr:id><gtr:title>Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1183f3adabc5dae8df0f31ab98e36a7"><gtr:id>a1183f3adabc5dae8df0f31ab98e36a7</gtr:id><gtr:otherNames>Quaye L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>F7Ycuj1bQLg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D651575-53DE-468B-8E12-849A6263C69D</gtr:id><gtr:title>Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90fb521fb4609dc795b90be3158eb5e1"><gtr:id>90fb521fb4609dc795b90be3158eb5e1</gtr:id><gtr:otherNames>Song H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>Zz2FdAW4o4V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26554B4F-FEB8-47EC-A955-ED3B1E6D7C0E</gtr:id><gtr:title>LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b4722ae336b8dabe55dbe5c33c49797"><gtr:id>5b4722ae336b8dabe55dbe5c33c49797</gtr:id><gtr:otherNames>Permuth-Wey J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>qGAACQCDEhG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11E5AB2D-7221-4B6D-ACA3-1947FF703B53</gtr:id><gtr:title>Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.</gtr:title><gtr:parentPublicationTitle>Neoplasia (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/935974906dc028d67682e08a9e542f7f"><gtr:id>935974906dc028d67682e08a9e542f7f</gtr:id><gtr:otherNames>Dafou D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1476-5586</gtr:issn><gtr:outcomeId>J1WXLqy28bz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D06DA481-F9EA-49F7-B7B5-28F3DA2C1EED</gtr:id><gtr:title>Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52b61451da0c8866230ea58902b080d8"><gtr:id>52b61451da0c8866230ea58902b080d8</gtr:id><gtr:otherNames>Pearce CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>eLCKXu6Ya9W</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>624B3DEB-8AC0-4465-9C99-D23FC7698C2C</gtr:id><gtr:title>MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b4722ae336b8dabe55dbe5c33c49797"><gtr:id>5b4722ae336b8dabe55dbe5c33c49797</gtr:id><gtr:otherNames>Permuth-Wey J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>e4Guparc3CZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB8D7447-9643-4B44-B307-7DBBEB77BC5B</gtr:id><gtr:title>The clonal evolution of metastases from primary serous epithelial ovarian cancers.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0191a6138a6c86fb5dc9731b1fcc279"><gtr:id>a0191a6138a6c86fb5dc9731b1fcc279</gtr:id><gtr:otherNames>Khalique L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>bRh3mRvWJpC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E751DED5-B062-4BF0-BFCA-5FC4A1D8CA6E</gtr:id><gtr:title>Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8296ea5b7dee6c6c0592e6f277a3b385"><gtr:id>8296ea5b7dee6c6c0592e6f277a3b385</gtr:id><gtr:otherNames>Kelemen LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>T8EpBecstZz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D186F34E-4780-47DE-B885-6A18E6F72D76</gtr:id><gtr:title>Ovarian cancer risk associated with inherited inflammation-related variants.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97011cd6f127ca98590e3fab17333734"><gtr:id>97011cd6f127ca98590e3fab17333734</gtr:id><gtr:otherNames>White KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_12901_21_22282663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89C50DF4-8BD6-4E07-9468-7CC257A66087</gtr:id><gtr:title>Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1183f3adabc5dae8df0f31ab98e36a7"><gtr:id>a1183f3adabc5dae8df0f31ab98e36a7</gtr:id><gtr:otherNames>Quaye L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>foQgTe43UtW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C3B9032-D417-49EF-A022-D3B1A1E7EFD3</gtr:id><gtr:title>ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42ce780e361a4b60e4b322007943af1b"><gtr:id>42ce780e361a4b60e4b322007943af1b</gtr:id><gtr:otherNames>Doherty JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>jwLhPW2y4cE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71DA25FE-1DD1-4EDB-834D-D24D2FA34BAC</gtr:id><gtr:title>Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90da2665c956ccc56a156779a60ce635"><gtr:id>90da2665c956ccc56a156779a60ce635</gtr:id><gtr:otherNames>Schildkraut JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>BMy6WLwLG58</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>378124A5-6C5D-4609-9B91-5B2621A68869</gtr:id><gtr:title>Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1183f3adabc5dae8df0f31ab98e36a7"><gtr:id>a1183f3adabc5dae8df0f31ab98e36a7</gtr:id><gtr:otherNames>Quaye L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>iZLTHda9USW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>585C856B-6141-4BF1-83DD-FE770991017C</gtr:id><gtr:title>Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52b61451da0c8866230ea58902b080d8"><gtr:id>52b61451da0c8866230ea58902b080d8</gtr:id><gtr:otherNames>Pearce CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>km7L8kPVtz6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F695CF7-474A-4C2A-834C-1DE91DFC962D</gtr:id><gtr:title>Risk of ovarian cancer in women with first-degree relatives with cancer.</gtr:title><gtr:parentPublicationTitle>Acta obstetricia et gynecologica Scandinavica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b7f1f76fb055afeddfa531929b2dc59"><gtr:id>6b7f1f76fb055afeddfa531929b2dc59</gtr:id><gtr:otherNames>Soegaard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0001-6349</gtr:issn><gtr:outcomeId>AYPDJV8uAtt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2DD8DAF-5D0F-4877-BB6E-3A113D6BBF52</gtr:id><gtr:title>Common variants at 19p13 are associated with susceptibility to ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75e7f5e68245f74578b6412b3bb96afb"><gtr:id>75e7f5e68245f74578b6412b3bb96afb</gtr:id><gtr:otherNames>Bolton KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>VV3WUmQsAvC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>439A7D98-1DB4-4E04-90EE-2EF1BF89F93D</gtr:id><gtr:title>Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility &amp;quot;hot-spot&amp;quot;.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9cd50a1b45b096272f4aef8052cd476"><gtr:id>c9cd50a1b45b096272f4aef8052cd476</gtr:id><gtr:otherNames>Johnatty SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>KhGpRsfbbXB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>832D4050-467F-4571-ABDA-7277BDF08B8A</gtr:id><gtr:title>Principles for the post-GWAS functional characterization of cancer risk loci.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d288d6e012bcfb4937010e8f2de59b78"><gtr:id>d288d6e012bcfb4937010e8f2de59b78</gtr:id><gtr:otherNames>Freedman ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>oGiF9c7MfPC</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801875</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>2472941E-25F2-45EC-A735-3C0872CE6B26</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.3  Psychological, social and economic factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>